A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential Hypertension Inadequately Controlled with DWC202405
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
198
5/20mg, 1 tablet, Oral, Once a day
5/20mg + 1.5mg, 1 tablet, Oral, Once a day
5/20mg + 1.5mg, 1 tablet, Oral, Once a day
Korea University ANAM Hospital
Seoul, South Korea
change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
10/40mg + 1.5mg, 1 tablet, Oral, Once a day
10/40mg + 1.5mg, 1 tablet, Oral, Once a day